Literature DB >> 25814403

Estimates of absolute treatment benefit for individual patients required careful modeling of statistical interactions.

David van Klaveren1, Yvonne Vergouwe2, Vasim Farooq3, Patrick W Serruys4, Ewout W Steyerberg2.   

Abstract

OBJECTIVES: We aimed to compare modeling approaches to estimate the individual survival benefit of treatment with either coronary artery bypass graft surgery (CABG) or percutaneous coronary intervention (PCI) for patients with complex coronary artery disease. STUDY DESIGN AND
SETTING: We estimated survival with Cox regression models that included the treatment variable (CABG/PCI) interacting with either an internally developed overall prognostic index (PI) or with individual prognostic factors. We analyzed data of patients who were randomized in the Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery trial (1,800 patients, 178 deaths).
RESULTS: A negligible interaction with the PI (P = 0.51) led to 4-year survival estimates in favor of CABG for all patients. In contrast, individual interactions indicated substantial relative treatment effect heterogeneity (overall interaction P = 0.004), and estimates of 4-year survival were numerically in favor of CABG for 1,275 of 1,800 patients (71%; 519 with 95% confidence). To test the more complex model with individual interactions, we first used penalized regression, resulting in smaller but largely consistent individual estimates of the survival difference between CABG and PCI. Second, strong treatment interactions were confirmed at external validation in 2,891 patients from a multinational registry.
CONCLUSION: Modeling strategies that omit interactions may result in misleading estimates of absolute treatment benefit for individual patients with the potential hazard of suboptimal decision making.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Coronary artery bypass graft surgery; Coronary artery disease; Individualized treatment decisions; Percutaneous coronary intervention; SYNTAX trial; Statistical interactions; Treatment effect heterogeneity

Mesh:

Year:  2015        PMID: 25814403      PMCID: PMC5569577          DOI: 10.1016/j.jclinepi.2015.02.012

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  31 in total

1.  Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test.

Authors:  Sara T Brookes; Elise Whitely; Matthias Egger; George Davey Smith; Paul A Mulheran; Tim J Peters
Journal:  J Clin Epidemiol       Date:  2004-03       Impact factor: 6.437

2.  Report of the Specialist Advisory Committee on Antimicrobial Resistance (SACAR) Surveillance Subgroup.

Authors:  Andrew C Hayward; Kim Goldsmith; Anne M Johnson
Journal:  J Antimicrob Chemother       Date:  2007-08       Impact factor: 5.790

3.  Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification.

Authors:  David M Kent; Rodney A Hayward
Journal:  JAMA       Date:  2007-09-12       Impact factor: 56.272

Review 4.  Should we adjust for covariates in nonlinear regression analyses of randomized trials?

Authors:  W W Hauck; S Anderson; S M Marcus
Journal:  Control Clin Trials       Date:  1998-06

Review 5.  Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.

Authors:  F E Harrell; K L Lee; D B Mark
Journal:  Stat Med       Date:  1996-02-28       Impact factor: 2.373

6.  Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages.

Authors:  Richard L Kravitz; Naihua Duan; Joel Braslow
Journal:  Milbank Q       Date:  2004       Impact factor: 4.911

7.  Treating individuals 3: from subgroups to individuals: general principles and the example of carotid endarterectomy.

Authors:  Peter M Rothwell; Ziyah Mehta; Sally C Howard; Sergei A Gutnikov; Charles P Warlow
Journal:  Lancet       Date:  2005 Jan 15-21       Impact factor: 79.321

8.  Cost-effectiveness of percutaneous coronary intervention with drug eluting stents versus bypass surgery for patients with diabetes mellitus and multivessel coronary artery disease: results from the FREEDOM trial.

Authors:  Elizabeth A Magnuson; Michael E Farkouh; Valentin Fuster; Kaijun Wang; Katherine Vilain; Haiyan Li; Jaime Appelwick; Victoria Muratov; Lynn A Sleeper; Robin Boineau; Mouin Abdallah; David J Cohen
Journal:  Circulation       Date:  2012-12-31       Impact factor: 29.690

9.  The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: design, rationale, and run-in phase.

Authors:  Andrew T L Ong; Patrick W Serruys; Frederick W Mohr; Marie-Claude Morice; A Pieter Kappetein; David R Holmes; Michael J Mack; Marcel van den Brand; Marie-Angele Morel; Gerrit-Anne van Es; Jeroen Kleijne; Joerg Koglin; Mary E Russell
Journal:  Am Heart J       Date:  2006-06       Impact factor: 4.749

10.  Prognosis research strategy (PROGRESS) 4: stratified medicine research.

Authors:  Aroon D Hingorani; Daniëlle A van der Windt; Richard D Riley; Keith Abrams; Karel G M Moons; Ewout W Steyerberg; Sara Schroter; Willi Sauerbrei; Douglas G Altman; Harry Hemingway
Journal:  BMJ       Date:  2013-02-05
View more
  16 in total

Review 1.  Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects.

Authors:  David M Kent; Ewout Steyerberg; David van Klaveren
Journal:  BMJ       Date:  2018-12-10

2.  Development and validation of a simplified Stroke-Thrombolytic Predictive Instrument.

Authors:  David M Kent; Robin Ruthazer; Carole Decker; Philip G Jones; Jeffrey L Saver; Erich Bluhmki; John A Spertus
Journal:  Neurology       Date:  2015-08-19       Impact factor: 9.910

Review 3.  Patient Variability Seldom Assessed in Cost-effectiveness Studies.

Authors:  Tara A Lavelle; David M Kent; Christine M Lundquist; Teja Thorat; Joshua T Cohen; John B Wong; Natalia Olchanski; Peter J Neumann
Journal:  Med Decis Making       Date:  2018-01-19       Impact factor: 2.583

4.  Using group data to treat individuals: understanding heterogeneous treatment effects in the age of precision medicine and patient-centred evidence.

Authors:  Issa J Dahabreh; Rodney Hayward; David M Kent
Journal:  Int J Epidemiol       Date:  2016-12-01       Impact factor: 7.196

5.  Postoperative Mortality after Liver Resection for Perihilar Cholangiocarcinoma: Development of a Risk Score and Importance of Biliary Drainage of the Future Liver Remnant.

Authors:  Jimme K Wiggers; Bas Groot Koerkamp; Kasia P Cieslak; Alexandre Doussot; David van Klaveren; Peter J Allen; Marc G Besselink; Olivier R Busch; Michael I D'Angelica; Ronald P DeMatteo; Dirk J Gouma; T Peter Kingham; Thomas M van Gulik; William R Jarnagin
Journal:  J Am Coll Surg       Date:  2016-04-05       Impact factor: 6.113

6.  Models with interactions overestimated heterogeneity of treatment effects and were prone to treatment mistargeting.

Authors:  David van Klaveren; Theodor A Balan; Ewout W Steyerberg; David M Kent
Journal:  J Clin Epidemiol       Date:  2019-06-10       Impact factor: 6.437

7.  The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement: Explanation and Elaboration.

Authors:  David M Kent; David van Klaveren; Jessica K Paulus; Ralph D'Agostino; Steve Goodman; Rodney Hayward; John P A Ioannidis; Bray Patrick-Lake; Sally Morton; Michael Pencina; Gowri Raman; Joseph S Ross; Harry P Selker; Ravi Varadhan; Andrew Vickers; John B Wong; Ewout W Steyerberg
Journal:  Ann Intern Med       Date:  2019-11-12       Impact factor: 25.391

8.  Sex based subgroup differences in randomized controlled trials: empirical evidence from Cochrane meta-analyses.

Authors:  Joshua D Wallach; Patrick G Sullivan; John F Trepanowski; Ewout W Steyerberg; John P A Ioannidis
Journal:  BMJ       Date:  2016-11-24

9.  The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement.

Authors:  David M Kent; Jessica K Paulus; David van Klaveren; Ralph D'Agostino; Steve Goodman; Rodney Hayward; John P A Ioannidis; Bray Patrick-Lake; Sally Morton; Michael Pencina; Gowri Raman; Joseph S Ross; Harry P Selker; Ravi Varadhan; Andrew Vickers; John B Wong; Ewout W Steyerberg
Journal:  Ann Intern Med       Date:  2019-11-12       Impact factor: 25.391

Review 10.  Prediction models for cardiovascular disease risk in the general population: systematic review.

Authors:  Johanna A A G Damen; Lotty Hooft; Ewoud Schuit; Thomas P A Debray; Gary S Collins; Ioanna Tzoulaki; Camille M Lassale; George C M Siontis; Virginia Chiocchia; Corran Roberts; Michael Maia Schlüssel; Stephen Gerry; James A Black; Pauline Heus; Yvonne T van der Schouw; Linda M Peelen; Karel G M Moons
Journal:  BMJ       Date:  2016-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.